You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)獲藥品專利池組織許可生產抗新冠藥「Molnupiravir」原料藥和成品藥
阿思達克 01-20 17:51
復星醫藥(02196.HK)表示,藥品專利池組織(Medicines Patent Pool, MPP)與包括集團在內的若干企業簽訂協議,將為全球105個中低收入國家或地區生產口服抗新冠病毒藥物「Molnupiravir」仿製藥,以促進口服抗新冠病毒藥物在中低收入國家的可負擔性和可及性,助力當地疫情防控。 MPP指,是次獲許可的企業有能力滿足MPP對產能和監管合規的要求,能生產符合國際質量標準的藥品。復星醫藥為是次全球13家獲許可同時生產「Molnupiravir」原料藥和成品藥的企業之一,另有5家藥企獲授權生產原料藥,9家藥企獲授權生產成品藥。 「Molnupiravir」由美國藥廠默沙東(MRK.US)研發,早前獲美國食品藥物管理局(FDA)可用於18歲以上成年人或染疫高風險族群。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account